Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Female Health Company($FHCO) announced the results from the first phase of its bioequivalence (BE) study aimed at identifying the optimal formulation of its Tamsulosin Delayed Release Sachet (DRS) product for the treatment of men with benign prostatic hyperplasia (BPH) or enlarged prostate. The company said that it will now advance the selected Tamsulosin DRS formulation into the second and final stage of the BE clinical trial. 
The results demonstrated that Tamsulosin DRS may have an improved safety profile. The stock jumped over 10 percent after the news. In Stage 2 of the BE clinical trial, Tamsulosin DRS will be tested in a larger number of subjects versus FLOMAX®. 

Ocera Therapeutics ($OCRX) stock responded positively in its after-market trading session to the news of positive preclinical results for lead product candidate OCR-002 (ornithine phenylacetate). Results from the investigator-sponsored preclinical study in a rat model of non-alcoholic fatty liver disease (NAFLD) showed the addition of OCR-002 significantly reduced the progression of fibrosis compared to untreated NAFLD rats while substantially reducing liver/body ratio, hepatic lipid content and hepatic collagen.
The company stock has slid over 43 percent this year so far. However, it is expected to show strength following the latest news. The study is continuing to collect follow-up data on patients, and is expected to be completed in September 2017.

 

Hologic Inc. ($HOLX) has been sued by Minerva Surgical for an alleged patent infringement. The startup has claimed that Hologic’s next-generation endometrial ablation device, NovaSure ADVANCED, infringes on patented technology in its device, approved by the FDA in July 2015 but never launched.  Minerva seeks an injunction blocking U.S. sales of Hologic's product. NovaSure ADVANCED was approved by the FDA in February.
Neuralstem ($CUR) announced adding a new cohort of four patients with chronic spinal cord injury to its ongoing Phase 1 clinical trial of NSI-566. Each participant will receive one surgery involving six injections of NSI-566 into the affected area of the cord. According to ClinicalTrials.gov, the estimated study completion date is December 2022.

Entellus Medical ($ENTL) announced receiving 510(k) clearance from the FDA for its XprESS ENT Dilation System for treating patients with persistent Eustachian tube dysfunction. The Eustachian tube 510(k) clearance follows assessment of a prospective, multicenter, randomized trial of the XprESS balloon dilation device in patients with persistent ETD.

Aerie Pharmaceuticals ($AERI) announced top line data from the Phase 3 Rocket 4 study, which showed that Rhopressa (netarsudil ophthalmic solution) maintained its safety characteristics while sustaining its non-inferiority to timolol over a six-month period.  The results will support a European marketing application. The company’s US marketing application is currently under FDA review.

 
McKesson Corporation ($MCK) announced signing a new deal to acquire Uniprix. The company has entered the deal through its Canadian subsidiary. The companies have not disclosed the financial details of the deal. Uniprix generates nearly CAD$1.6 billion in annual revenue.

United Therapeutics ($UTHR) announced forging a new strategic collaboration with Respira Therapeutics. The deal involves development and exclusive commercialization of Respira's lead product candidate RT234 for the treatment of pulmonary hypertension in North America. United Therapeutics will provide development funding to advance RT234 through FDA approval and will be the lead investor in Respira's Series B preferred stock financing. 

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Wedbush
Reiterates
Novan (NOVN)
Neutral
$8.00
High
Stifel Nicolaus
Reiterates
Geron (GERN)
Hold
$2.50
Low
Piper Jaffray Companies
Reiterates
Axovant Sciences Ltd (AXON)
Overweight
$32.00
Low
Piper Jaffray Companies
Reiterates
Geron (GERN)
Overweight
$5.00
Low
Piper Jaffray Companies
Initiates
Prothena Co. PLC (PRTA)
Overweight -> Overweight
$69.00
Medium
Piper Jaffray Companies
Initiates
TESARO (TSRO)
Overweight -> Overweight
$180.00
Low
Oppenheimer Holdings
Reiterates
Avinger (AVGR)
Outperform -> Market Perform

High
Oppenheimer Holdings
Reiterates
Intercept Pharmaceuticals (ICPT)
Outperform

High

Gainers (% price change)
Last Trade
Change
Mkt Cap
Neurocrine Biosciences
NBIX
51.80
+10.32 (24.88%)
4.64B
ZIOPHARM Oncology Inc.
ZIOP
7.44
+0.67 (9.90%)
1.01B
Trinity Biotech plc (ADR)
TRIB
5.90
+0.35 (6.31%)
138.62M
Albany Molecular Research
AMRI
15.20
+0.87 (6.07%)
645.05M
Dynavax Tech. Corp.
DVAX
5.45
+0.25 (4.81%)
239.42M
Losers (% price change)

MediciNova, Inc.
MNOV
4.91
-0.50 (-9.24%)
169.53M
CyberOptics Corporation
CYBE
23.00
-1.55 (-6.31%)
157.13M
BioCryst Pharmaceuticals
BCRX
6.81
-0.41 (-5.68%)
544.27M
Oclaro, Inc.
OCLR
8.62
-0.38 (-4.22%)
1.42B
Cryolife Inc
CRY
14.95
-0.65 (-4.17%)
496.87M
Most Actives (dollar volume)

Pfizer Inc.
PFE
33.92
-0.01 (-0.03%)
201.35B
Johnson & Johnson
JNJ
125.40
+1.18 (0.95%)
339.95B
Neurocrine Biosciences
NBIX
51.80
+10.32 (24.88%)
4.64B
Merck & Co., Inc.
MRK
63.05
+0.47 (0.75%)
172.94B
Gilead Sciences, Inc.
GILD
66.22
+0.20 (0.30%)
86.04B